GALAPAGOS NV/S (NASDAQ:GLPG) Given Consensus Rating of “Buy” by Brokerages

Shares of GALAPAGOS NV/S (NASDAQ:GLPG) have been given a consensus rating of “Buy” by the seventeen brokerages that are covering the firm, MarketBeat.com reports. Two analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and one has assigned a strong buy rating to the company. The average twelve-month price objective among analysts that have issued a report on the stock in the last year is $167.89.

Several equities analysts have recently weighed in on GLPG shares. Jefferies Financial Group cut GALAPAGOS NV/S from a “buy” rating to a “hold” rating in a report on Monday, July 29th. UBS Group raised GALAPAGOS NV/S from a “neutral” rating to a “buy” rating in a report on Wednesday, July 31st. Stifel Nicolaus increased their price target on GALAPAGOS NV/S from $121.00 to $188.00 and gave the company a “buy” rating in a report on Monday, July 15th. Raymond James cut GALAPAGOS NV/S from a “strong-buy” rating to a “market perform” rating in a report on Monday, July 15th. Finally, Cowen reissued a “buy” rating on shares of GALAPAGOS NV/S in a report on Friday, July 26th.

Several large investors have recently bought and sold shares of GLPG. Stevens Capital Management LP acquired a new stake in GALAPAGOS NV/S during the first quarter worth approximately $398,000. Pinnacle Associates Ltd. acquired a new stake in GALAPAGOS NV/S during the first quarter worth approximately $231,000. DekaBank Deutsche Girozentrale grew its stake in GALAPAGOS NV/S by 121.4% during the first quarter. DekaBank Deutsche Girozentrale now owns 6,200 shares of the biotechnology company’s stock worth $632,000 after purchasing an additional 3,400 shares during the period. Marshall Wace North America L.P. grew its stake in GALAPAGOS NV/S by 149.4% during the first quarter. Marshall Wace North America L.P. now owns 18,751 shares of the biotechnology company’s stock worth $2,208,000 after purchasing an additional 11,233 shares during the period. Finally, FMR LLC grew its stake in GALAPAGOS NV/S by 35.3% during the first quarter. FMR LLC now owns 502,193 shares of the biotechnology company’s stock worth $59,148,000 after purchasing an additional 131,119 shares during the period. Hedge funds and other institutional investors own 17.40% of the company’s stock.

GLPG stock traded down $1.41 during midday trading on Friday, hitting $162.04. The company’s stock had a trading volume of 116,291 shares, compared to its average volume of 104,453. The company has a market cap of $8.30 billion, a PE ratio of -245.52 and a beta of 1.58. GALAPAGOS NV/S has a 12 month low of $85.00 and a 12 month high of $191.63. The company has a current ratio of 6.40, a quick ratio of 6.40 and a debt-to-equity ratio of 0.02. The firm’s 50-day moving average is $172.76 and its 200-day moving average is $130.88.

GALAPAGOS NV/S Company Profile

Galapagos NV, a clinical-stage biotechnology company, discovers, develops, and commercializes novel medicines. Its clinical stage programs include filgotinib, which is in Phase III clinical trials for the treatment of rheumatoid arthritis and Crohn's disease, Phase 2/3 trials for ulcerative colitis, and Phase II trials for multiple additional indications; GLPG1690, an autotaxin inhibitor, which is in Phase III clinical trial for the treatment of idiopathic pulmonary fibrosis; GLPG1972 that completed Phase 1b clinical trial for the treatment of osteoarthritis; and MOR106, which is in Phase II trials for atopic dermatitis patients.

See Also: How is the S&P 500 index different from the DJIA?

Analyst Recommendations for GALAPAGOS NV/S (NASDAQ:GLPG)

Receive News & Ratings for GALAPAGOS NV/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GALAPAGOS NV/S and related companies with MarketBeat.com's FREE daily email newsletter.